Research Interests
I am interested in primary and secondary immunodeficiencies and allergic diseases. Our clinical research team is involved in clinical trials studying safety and tolerability of immunoglobulin therapy, gene therapy trials for primary immunodeficiency diseases, and asthma and allergic diseases. Some areas of focus include a national registry for carriers of X-linked chronic granulomatous disease, immune dysregulation, and understanding evaluation and management of primary and secondary immunodeficiency diseases.
Selected Grants
Long-term safety and tolerability of TAK-881 in subjects with Primary Immunodeficiency Diseases
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2024 - 2027A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety of Kedrion
Clinical TrialPrincipal Investigator · Awarded by Kedrion S.p.A. · 2025 - 2027A Survey Assessing the Prescribing Habits, Immunologic Screening, and Therapeutic Management of Providers Using B-cell Depleting Therapies"
ResearchPrincipal Investigator · Awarded by ADMA Biologics · 2026 - 2027Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2024 - 2027Developing a National Registry for Female Carriers of X-linked Chronic Granulomatous Disease: Improving Recognition, Diagnosis, and Treatment
ResearchMentor · Awarded by American College of Allergy, Asthma & Immunology · 2024 - 2026External Relationships
- Allergy and asthma network
- American Academy of Pediatrics
- Grifols
- Horizon Therapeutics (purchased Viela Bio) and acquired by Amgen
- Janssen Pharmaceuticals
- Neuroimmune Foundation
- Novartis pharmaceuticals
- Onviv
- Pharming Healthcare, Inc
- Takeda Pharmaceutical Co. Ltd.
- X4 Pharmaceuticals
- adma biologics
- american college of allergy, asthma, and immunology
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.